Standout Papers

Trastuzumab in combination with chemotherapy versus ... 1997 2026 2006 2016 5.1k
  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial (2010)
    Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet
  2. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (2011)
    Atsushi Ohtsu, Manish A. Shah et al. Journal of Clinical Oncology
  3. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (2016)
    Muhammad S. Beg, Andrew Brenner et al. Investigational New Drugs
  4. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial (2013)
    Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology
  5. Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization (1997)
    Paraskevi Giannakakou, Dan L. Sackett et al. Journal of Biological Chemistry
  6. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial (2013)
    Ann‐Lii Cheng, Yoon‐Koo Kang et al. Journal of Clinical Oncology
  7. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial (2009)
    Yoon‐Koo Kang, Won Ki Kang et al. Annals of Oncology
  8. Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial (2014)
    Călin Cainap, Shukui Qin et al. Journal of Clinical Oncology
  9. Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib (2014)
    Andrew X. Zhu, Masatoshi Kudo et al. JAMA
  10. SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma (2014)
    Andrew X. Zhu, Olivier Rosmorduc et al. Journal of Clinical Oncology
  11. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study (2017)
    Peter Thuss‐Patience, Manish A. Shah et al. The Lancet Oncology
  12. Management of gastric cancer in Asia: resource-stratified guidelines (2013)
    Lin Shen, Yan‐Shen Shan et al. The Lancet Oncology
  13. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study (2018)
    Josep Tabernero, Paulo M. Hoff et al. The Lancet Oncology
  14. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines (2015)
    Toshirou Nishida, Jean‐Yves Blay et al. Gastric Cancer
  15. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial (2023)
    Kohei Shitara, Florian Lordick et al. The Lancet
  16. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. (2022)
    Ghassan K. Abou‐Alfa, Stephen L. Chan et al. Journal of Clinical Oncology
  17. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4) (2018)
    Narikazu Boku, Min‐Hee Ryu et al. Annals of Oncology
  18. Gastrointestinal stromal tumours (2021)
    Jean‐Yves Blay, Yoon‐Koo Kang et al. Nature Reviews Disease Primers

Immediate Impact

11 by Nobel laureates 9 from Science/Nature 121 standout
Sub-graph 1 of 18

Citing Papers

Oesophageal cancer
2024 Standout
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
2023 Standout
3 intermediate papers

Works of Yoon‐Koo Kang being referenced

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
2018 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
and 3 more

Author Peers

Author Last Decade Papers Cites
Yoon‐Koo Kang 13225 11984 5804 6704 543 25.4k
Hyun Cheol Chung 13659 14781 4526 6961 577 26.9k
Andrés Cervantes 9130 17546 1586 8193 459 26.9k
Olivier Bouché 9242 18148 1945 7789 410 24.6k
Yung‐Jue Bang 16587 20426 4423 7405 602 36.1k
Atsushi Ohtsu 16772 13908 4682 9640 523 26.2k
Robert S. Benjamin 13510 11394 3239 4110 474 24.7k
Ian Chau 6982 12763 1143 5277 463 18.2k
Marc Ychou 7558 15774 1182 4736 319 21.6k
Charles D. Blanke 9402 8311 6389 5677 288 18.1k
Joon Oh Park 7439 9002 1444 4256 378 15.8k

All Works

Loading papers...

Rankless by CCL
2026